Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site
ACS MEDICINAL CHEMISTRY LETTERS
Authors: Maryanoff, Bruce E.; O'Neill, John C.; McComsey, David F.; Yabut, Stephen C.; Luci, Diane K.; Jordan, Alfonzo D., Jr.; Masucci, John A.; Jones, William J.; Abad, Marta C.; Gibbs, Alan C.; Petrounia, Ioanna
Abstract
Attenuation of fructose metabolism by the inhibition of ketohexokinase (KHK; fructokinase) should reduce body weight, free fatty acids, and triglycerides, thereby offering a novel approach to treat diabetes and obesity in response to modern diets. We have identified potent, selective inhibitors of human hepatic KHK within a series of pyrimidinopyrimidines (1). For example, 8, 38, and 47 exhibited KHK IC(50) values of 12, 7, and 8 nM, respectively, and also showed potent cellular KHK inhibition (IC(50) < 500 nM), which relates to their intrinsic potency vs KHK and their ability to penetrate cells. X-ray cocrystal structures of KHK complexes of 3, 8, and 47 revealed the important interactions within the enzyme's adenosine 5'-triphosphate (ATP)-binding pocket.
HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease
NATURE
Authors: Mirtschink, Peter; Krishnan, Jaya; Grimm, Fiona; Sarre, Alexandre; Hoerl, Manuel; Kayikci, Melis; Fankhauser, Niklaus; Christinat, Yann; Cortijo, Cedric; Feehan, Owen; Vukolic, Ana; Sossalla, Samuel; Stehr, Sebastian N.; Ule, Jernej; Zamboni, Nicola; Pedrazzini, Thierry; Krek, Wilhelm
Abstract
Fructose is a major component of dietary sugar and its overconsumption exacerbates key pathological features of metabolic syndrome. The central fructose-metabolising enzyme is ketohexokinase (KHK), which exists in two isoforms: KHK-A and KHK-C, generated through mutually exclusive alternative splicing of KHK pre-mRNAs. KHK-C displays superior affinity for fructose compared with KHK-A and is produced primarily in the liver, thus restricting fructose metabolism almost exclusively to this organ. Here we show that myocardial hypoxia actuates fructose metabolism in human and mouse models of pathological cardiac hypertrophy through hypoxia-inducible factor 1 alpha (HIF1 alpha) activation of SF3B1 and SF3B1-mediated splice switching of KHK-A to KHK-C. Heart-specific depletion of SF3B1 orgenetic ablation of Khk, but not Khk-A alone, in mice, suppresses pathological stress-induced fructose metabolism, growth and contractile dysfunction, thus defining signalling components and molecular underpinnings of a fructose metabolism regulatory system crucial for pathological growth.